Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans

L. Gianni, J. F. Jenkins, R. F. Greene, A. S. Lichter, C. E. Myers, J. M. Collins

Research output: Contribution to journalArticle

Abstract

The hypoxic radiosensitizers misonidazole or demethylmisonidazole were administered i.p. in a 2-liter volume to 6 patients affected by advanced ovarian carcinoma, and the pharmacokinetic course of the two drugs was studied. The clearance of misonidazole and demethylmisonidazole from the peritoneal fluid was 19.1 and 12.4 ml/min, respectively. At 3 hr after drug administration, both radiosensitizers had peritoneal fluid concentrations more than 8 times larger than in the plasma. The concentration x time exposure in the peritoneal fluid was 3.2 times larger than in plasma for misonidazole and 7.6 times for demethylmisonidazole. The advantage of i.p. delivery compared with systemic delivery decreases with distance from the peritoneal surface, but the advantage may be maintained for up to 1 mm or 100 cell layers. These differences between the two routes of administration provided a rational basis for the expectation that a substantial increase of the therapeutic benefits of misonidazole and demethylmisonidazole in potentiating radiation therapy or chemotherapy can be expected in treating tumors confined to the i.p. space.

Original languageEnglish
Pages (from-to)913-916
Number of pages4
JournalCancer Research
Volume43
Issue number2
Publication statusPublished - 1983

Fingerprint

Misonidazole
Ascitic Fluid
Pharmacokinetics
Pharmaceutical Preparations
Radiotherapy
Carcinoma
Drug Therapy
desmethylmisonidazole
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gianni, L., Jenkins, J. F., Greene, R. F., Lichter, A. S., Myers, C. E., & Collins, J. M. (1983). Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. Cancer Research, 43(2), 913-916.

Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. / Gianni, L.; Jenkins, J. F.; Greene, R. F.; Lichter, A. S.; Myers, C. E.; Collins, J. M.

In: Cancer Research, Vol. 43, No. 2, 1983, p. 913-916.

Research output: Contribution to journalArticle

Gianni, L. ; Jenkins, J. F. ; Greene, R. F. ; Lichter, A. S. ; Myers, C. E. ; Collins, J. M. / Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. In: Cancer Research. 1983 ; Vol. 43, No. 2. pp. 913-916.
@article{d69ac3dd6b2044e8a806548806cf0a62,
title = "Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans",
abstract = "The hypoxic radiosensitizers misonidazole or demethylmisonidazole were administered i.p. in a 2-liter volume to 6 patients affected by advanced ovarian carcinoma, and the pharmacokinetic course of the two drugs was studied. The clearance of misonidazole and demethylmisonidazole from the peritoneal fluid was 19.1 and 12.4 ml/min, respectively. At 3 hr after drug administration, both radiosensitizers had peritoneal fluid concentrations more than 8 times larger than in the plasma. The concentration x time exposure in the peritoneal fluid was 3.2 times larger than in plasma for misonidazole and 7.6 times for demethylmisonidazole. The advantage of i.p. delivery compared with systemic delivery decreases with distance from the peritoneal surface, but the advantage may be maintained for up to 1 mm or 100 cell layers. These differences between the two routes of administration provided a rational basis for the expectation that a substantial increase of the therapeutic benefits of misonidazole and demethylmisonidazole in potentiating radiation therapy or chemotherapy can be expected in treating tumors confined to the i.p. space.",
author = "L. Gianni and Jenkins, {J. F.} and Greene, {R. F.} and Lichter, {A. S.} and Myers, {C. E.} and Collins, {J. M.}",
year = "1983",
language = "English",
volume = "43",
pages = "913--916",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans

AU - Gianni, L.

AU - Jenkins, J. F.

AU - Greene, R. F.

AU - Lichter, A. S.

AU - Myers, C. E.

AU - Collins, J. M.

PY - 1983

Y1 - 1983

N2 - The hypoxic radiosensitizers misonidazole or demethylmisonidazole were administered i.p. in a 2-liter volume to 6 patients affected by advanced ovarian carcinoma, and the pharmacokinetic course of the two drugs was studied. The clearance of misonidazole and demethylmisonidazole from the peritoneal fluid was 19.1 and 12.4 ml/min, respectively. At 3 hr after drug administration, both radiosensitizers had peritoneal fluid concentrations more than 8 times larger than in the plasma. The concentration x time exposure in the peritoneal fluid was 3.2 times larger than in plasma for misonidazole and 7.6 times for demethylmisonidazole. The advantage of i.p. delivery compared with systemic delivery decreases with distance from the peritoneal surface, but the advantage may be maintained for up to 1 mm or 100 cell layers. These differences between the two routes of administration provided a rational basis for the expectation that a substantial increase of the therapeutic benefits of misonidazole and demethylmisonidazole in potentiating radiation therapy or chemotherapy can be expected in treating tumors confined to the i.p. space.

AB - The hypoxic radiosensitizers misonidazole or demethylmisonidazole were administered i.p. in a 2-liter volume to 6 patients affected by advanced ovarian carcinoma, and the pharmacokinetic course of the two drugs was studied. The clearance of misonidazole and demethylmisonidazole from the peritoneal fluid was 19.1 and 12.4 ml/min, respectively. At 3 hr after drug administration, both radiosensitizers had peritoneal fluid concentrations more than 8 times larger than in the plasma. The concentration x time exposure in the peritoneal fluid was 3.2 times larger than in plasma for misonidazole and 7.6 times for demethylmisonidazole. The advantage of i.p. delivery compared with systemic delivery decreases with distance from the peritoneal surface, but the advantage may be maintained for up to 1 mm or 100 cell layers. These differences between the two routes of administration provided a rational basis for the expectation that a substantial increase of the therapeutic benefits of misonidazole and demethylmisonidazole in potentiating radiation therapy or chemotherapy can be expected in treating tumors confined to the i.p. space.

UR - http://www.scopus.com/inward/record.url?scp=0020661605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020661605&partnerID=8YFLogxK

M3 - Article

C2 - 6848201

AN - SCOPUS:0020661605

VL - 43

SP - 913

EP - 916

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 2

ER -